NCT07050186 - Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

November 20, 2030

Study Completion Date

November 20, 2035

Conditions

Metastatic NUT CarcinomaUnresectable NUT Carcinoma

Interventions

PROCEDURE

Biopsy Procedure

Undergo optional biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

BIOLOGICAL

Cemiplimab

Given IV

PROCEDURE

Computed Tomography

Undergo CT

OTHER

Digital Photography

Undergo digital photography

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

RECRUITING

Northwestern University, Chicago

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER